
    
      The safety and immunogenicity of 2 antigen doses in PPD-negative adults will be evaluated. In
      addition, 2 active comparator groups of volunteers will receive the vaccine alone without an
      immunostimulant and 1 control group will receive the adjuvant (AS02) alone to assess the true
      effect of the candidate tuberculosis vaccine (Mtb72F/AS02).
    
  